[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vasoplegia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vasoplegia":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,42,71,108,142,168,196,220,241],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100644555","phase-4-angiotensin-ii-for-post-cardiac-surgery-vasoplegia-angiiv-100644555",false,"NCT07671365","Angiotensin II for Post Cardiac Surgery Vasoplegia (ANGII_V)","ANGII_V","Inclusion Criteria:\n\n* In order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n  1. Provision of signed and dated informed consent form\n  2. Stated willingness to comply with all study procedures and availability for the duration of the study\n  3. Male or female, aged 18 or over\n  4. Exhibiting vasoplegia or vasoplegic shock following surgeries involving cardiopulmonary bypass\n  5. MAP below results below 65mmHg\n\nExclusion Criteria:\n\n* An individual who meets any of the following criteria will be excluded from participation in this study:\n\n  1. Current use of angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs)\n  2. Presence of treatment with high-dose glucocorticoids\n  3. Pregnancy or lactation\n  4. Known allergic reactions to components of the Giapreza, \\\u003Cspecify components\u002Fallergens\\>\n  5. Febrile illness within \\\u003Cspecify time frame\\>\n  6. Treatment with another investigational drug or other intervention within \\\u003Cspecify time frame\\>\n  7. Current smoker or tobacco use within \\\u003Cspecify timeframe\\>\n  8. Currently receiving VA ECMO for cardiogenic shock\n  9. Experiencing uncontrolled hemorrhage\n  10. Presenting with burns over 20% or more of body, acute coronary syndrome, bronchial spasms, liver failure, mesenteric ischemia, abdominal aortic aneurysm, or an absolute neutrophil count less than 1000 cubic millimeters","ALL","18 Years","94 Years",{"count":20,"type":21},329,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this study is to conduct a prospective trial implementing a modified version of the Emory Protocol for administering ANG II to patients with post cardiac bypass vasoplegia. The main questions we aim to answer are: 1.) does administration of improve mortality, 2.) does the administration of Ang II using the modified protocol shorten the time needed to reach optimal MAP, 3.) does the administration of Ang II using the modified protocol shorten length of stay in the ICU and hospital? Researchers will compare outcomes from the interventional group to historical controls who did not receive Ang II using the modified protocol.",[27,28,29],"Vasoplegic Shock","Cardiopulmonary Bypass","Vasoplegia","NOT_YET_RECRUITING","2026-06-22",{"date":33,"type":34},"2026-06-26","ACTUAL",{"date":36,"type":21},"2026-07",{"date":38,"type":21},"2030-08",{"name":40,"class":41},"Methodist Healthcare System of San Antonio","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100443761","phase-4-midodrine-for-the-early-liberation-of-vasopressor-support-in-the-icu-liberate-multi-site-100443761","NCT05058612","Midodrine for the Early Liberation of Vasopressor Support in the ICU (LIBERATE Multi-Site)","Midodrine for the Early Liberation From Vasopressor Support in the ICU - The LIBERATE Multi-Site Study","Inclusion Criteria:\n\n* Age \\> 18 years\n* Ongoing vasopressor support\n* Decreasing vasopressor dose(s)\n\nExclusion Criteria:\n\n* Greater than 24 hours from peak vasopressor dose\n* Contraindication to enteral medications\n* Previously received midodrine in last 7 days\n* Expected death or anticipated withdrawal of life-sustaining therapies in next 24 hours\n* Pregnancy\n* Known allergy to midodrine",true,{"count":51,"type":21},870,[24],"Vasopressors are medications that are given intravenously to increase the blood pressure of patients with illnesses that cause dangerous blood pressure drops. When a doctor prescribes a vasopressor, they ask that the dose be adjusted to achieve a specific blood pressure. This kind of medical support with intravenous (IV) vasopressors are usual treatments in intensive care unit (ICU) settings. Oral vasopressors, such as midodrine, have been historically used to maintain blood pressure in non-critically ill patients. In this study, the investigators will be using midodrine to reduce the need for IV vasopressors as blood pressure improves during the stay in the ICU.\n\nThis LIBERATE multi-site study will continue the work of the LIBERATE feasibility RCT study to evaluate the role of midodrine for patients with low blood pressure in the ICU. It is comprised of the multi centre pilot RCT followed by the definitive multi centre RCT.",[29],[56,57,58,59],"critical care medicine","intensive care","shock","midodrine","RECRUITING","2026-01-15",{"date":63,"type":34},"2026-01-20",{"date":65,"type":34},"2021-03-22",{"date":67,"type":21},"2028-02",{"name":69,"class":41},"University of Alberta",1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":80,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":88,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":70},"100619498","genecard---the-use-of-genetic-epigenetic-metabolomic-proteomic-and-microbiotic-markers-image-and-voice-biomarker-analyses-and-pre--and-intraoperative-clinical-data---to-predict-early-complications-after-cardiac-surgery-100619498","NCT07345403","GENECARD - the Use of Genetic, Epigenetic, Metabolomic, Proteomic and Microbiotic Markers, Image and Voice Biomarker Analyses, and Pre- and Intraoperative Clinical Data - to Predict Early Complications After Cardiac Surgery.","GENECARD","Inclusion Criteria:\n\n* Adults (≥18 years old)\n* Undergoing elective cardiac surgery\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Age below 18 years\n* Lack of informed consent\n* Prior or planned solid organ transplantation\n* Prior or planned bone marrow transplantation",{"count":79,"type":21},3000,"30 Days","OBSERVATIONAL","The goal of this observational cohort study is to prove whether genetic, epigenetic, transcriptomic, proteomic, metabolomic, imaging, voice, and clinical markers can improve prediction of early complications after cardiac surgery in adult patients.\n\nThe main questions it aims to answer are:\n\nWhich biological and clinical markers are associated with: new-onset atrial fibrillation (NOAF), acute kidney injury (AKI), postoperative delirium (POD), vasoplegia, postoperative bleeding and 30-day mortality? Can combining these markers improve early prediction of postoperative complications compared with current clinical risk scores?\n\nResearchers will analyze a wide range of data collected before, during, and after cardiac surgery and compare patients who develop early complications with those who do not to identify risk factors and early biomarkers.\n\nParticipants will:\n\nProvide biological samples (blood, urine, stool) before and after surgery for genetic, epigenetic, transcriptomic, proteomic, metabolomic, microbiome, and laboratory testing.\n\nUndergo standard preoperative and intraoperative imaging and clinical assessments.\n\nAllow collection of clinical data related to postoperative outcomes (For some participants) have voice and video recordings performed to help identify early signs of postoperative delirium.\n\nThis study aims to improve early detection of postoperative complications and support development of personalized diagnostic and treatment strategies for patients undergoing cardiac surgery.",[84,85,86,87,29],"Postoperative Delirium (POD)","Postoperative Bleeding","Acute Kidney Injury","Atrial Fibrillation (AF)",[89,90,91,86,92,29,93,94,95,96,97,98,99],"Cardiac Surgery","Postoperative Complications","Atrial Fibrillation","Postoperative Delirium","Biomarkers","Multi-omics","Risk Prediction","Epigenetics","genetics","microbiota","metabolomics","2026-01-08",{"date":61,"type":34},{"date":103,"type":21},"2026-01-01",{"date":105,"type":21},"2029-12-31",{"name":107,"class":41},"Medical University of Gdansk",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":120,"conditions":121,"keywords":128,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":141},"100589322","femoral-versus-radial-invasive-arterial-pressure-monitoring-in-cardiac-surgery-patients-100589322","NCT06952907","Femoral Versus Radial Invasive Arterial Pressure Monitoring in Cardiac Surgery Patients","Femoral Versus Radial Artery Catheterization for Invasive Arterial Pressure Monitoring in Cardiac Surgery Patients: the FERARI Randomized Superiority Study","FERARI","Inclusion Criteria:\n\n* Male and female patients ≥18 years\n* Scheduled cardiac surgery with cardiopulmonary bypass (time between anesthesia consultation and surgery \\> 48 hours)\n* ASA physical status ≥II\n* Affiliation with or beneficiary of the French national health insurance system\n* Signed informed consent indicating that the participant has understood the purpose and procedures of the study and agrees to participate and comply with its requirements and restrictions\n\nExclusion Criteria:\n\n* Emergency surgery (before the next working day after decision to operate)\n* Surgery requiring the use of two arterial pressure monitoring sites: e.g., aortic arch surgery, aortic dissection, etc.\n* Heart transplantation surgery\n* Mechanical circulatory support\n* Contraindication to radial artery catheterization: failed Allen test, Raynaud syndrome, Buerger disease, major hyperlipidemia\n* Contraindication to femoral artery catheterization: puncture of vascular prosthetic material in the femoral area (e.g., femoral bypass, femoral stenting, femoral trifurcation endarterectomy, femoral angioplasty)\n* Pregnant or breastfeeding women\n* Persons deprived of liberty by judicial or administrative decision; persons under compulsory psychiatric care; persons admitted to a healthcare or social institution for reasons other than research\n* Adults under legal protection measures (guardianship, trusteeship, or legal safeguard) or unable to give informed consent\n* Subjects currently under exclusion period of another clinical trial or listed in the national registry of research volunteers",{"count":117,"type":21},340,[119],"NA","Background: Acute circulatory failure, often presenting as arterial hypotension, is a major contributor to postoperative morbidity and mortality. Accurate blood pressure (BP) monitoring is essential for timely therapeutic intervention, particularly in patients undergoing major surgery. Among invasive BP measurement sites, the radial artery is commonly used due to its accessibility and ease of catheterization. However, physiologically, the radial artery may underestimate central arterial pressure compared to the femoral artery, especially in patients receiving vasopressors or in critical conditions. This discrepancy can lead to overtreatment with vasopressors and associated complications. Current literature on the accuracy of radial versus femoral BP monitoring is outdated and based solely on observational studies. There is a lack of high-quality randomized data to inform clinical guidelines.\n\nHypothesis: Femoral arterial pressure monitoring, by offering more accurate hemodynamic data, reduces the need for vasopressor support, particularly norepinephrine, compared to radial artery monitoring.\n\nPrimary Objective: To compare the effect of femoral versus radial invasive BP monitoring on the proportion of patients requiring norepinephrine from anesthetic induction to postoperative day 7 (D7) following elective cardiac surgery. Norepinephrine treatment is defined by continuous intravenous administration of norepinephrine for more than 1 minute.\n\nSecondary Objectives :\n\nTo compare the following outcomes between the two strategies within the first 7 postoperative days: incidence of acute kidney injury (AKI) according to KDIGO criteria, incidence of cardiac complications (arrhythmias requiring treatment, myocardial injury (troponin \\>99th percentile or \\>20% rise from baseline), myocardial infarction, cardiogenic shock, cardiac arrest), vaso-inotropic score (VIS), duration of any vasopressor therapy (days), ICU and hospital length of stay (days), all-cause mortality at day 7 and day 30, total duration (hours\u002Fdays) and maximal dose of norepineprhine therapy, intraoperative hypotension episodes (MAP\\\u003C65 mmHg \\> 5 min), incidence of arterial catheter-related complications (hematoma, bleeding, infection, thrombosis, arterial occlusion, malfunction, dislodgement).\n\nPrimary Endpoint: The proportion of patients receiving continuous intravenous norepinephrine from anesthesia induction to postoperative day 7.\n\nSecondary Endpoints:\n\nAKI occurrence or need for renal replacement therapy; cardiac complications: atrial\u002Fventricular arrhythmias requirinf treatment, myocardial injury (troponin \\>99th percentile or \\>20% rise from baseline), myocardial infarction (biomarker elevation + ECG or echocardiographic abnormalities), cardiogenic shock, cardiac arrest; maximum VIS in the OR, ICU admission, and day 1; intraoperative hypotension episodes (MAP\\\u003C65 mmHg \\> 5 min); total norepinephrine support duration (in hours); duration of any vasopressor therapy; arterial line complications: malfunction, dislodgement, hematoma, thrombosis, infection, bleeding, arterial occlusion; ICU and hospital length of stay (days); all-cause mortality at day 7 and day 30\n\nStudy Design: A prospective, multicenter (Besançon and Dijon University Hospitals), randomized, superiority, single-blind, intention-to-treat clinical trial in adults undergoing elective cardiac surgery. Patients are randomized to femoral or radial artery catheterization for continuous BP monitoring.\n\nSample Size: Based on an expected norepinephrine use rate of 70%, a 15% absolute risk reduction, α = 0.05, and power = 90%, 162 patients per group are required. Accounting for 5% data loss, 340 patients will be enrolled.\n\nStudy Arms:\n\nRadial group: invasive BP monitoring via radial artery catheterization Femoral group: invasive BP monitoring via femoral artery catheterization The arterial line is placed under ultrasound guidance in the operating room and maintained postoperatively in the ICU or critical care unit until no longer clinically indicated.\n\nEligibility Criteria Inclusion: adults patients ≥18 years undergoing elective on-pump cardiac surgery with informed consent.\n\nExclusion: emergency surgery, use of dual arterial lines, heart transplantation, mechanical circulatory support, contraindications to radial\u002Ffemoral catheterization, legal or ethical inability to consent.\n\nStudy Timeline Inclusion period: 36 months Patient follow-up: 7 days post-surgery Total study duration: 36 months\n\nData Collection: Clinical data are collected by research staff using an electronic case report form (e-CRF) via CleanWeb™ software.\n\nExpected Impact: There are currently no guidelines specifying the optimal site for invasive BP monitoring. This study aims to provide robust evidence on whether femoral BP monitoring improves clinical outcomes, reduces vasopressor use, and minimizes adverse events. Positive findings could inform future practice guidelines and lead to broader investigations in other clinical settings.",[122,29,123,124,125,126,127],"Vasoplegia Syndrome","Cardiac Surgical Procedures","Arterial Pressure","Hypotension During Surgery","Hypotension Postprocedural","Norepinephrine",[129,130,131,127],"Invasive arterial blood pressure monitoring","Vasoplegia syndrome","Cardiac surgery","2025-12-16",{"date":134,"type":34},"2025-12-22",{"date":136,"type":34},"2025-06-15",{"date":138,"type":21},"2027-08-01",{"name":140,"class":41},"Guillaume BESCH",2,{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":22,"phases":151,"briefSummary":152,"conditions":153,"keywords":156,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":4},"100602586","effect-inhaled-nitric-oxide-in-adult-liver-transplant-100602586","NCT07125443","Effect Inhaled Nitric Oxide in Adult Liver Transplant","Effect of Intraoperative Inhaled Nitric Oxide on Reperfusion Syndrome and Vasoplegia in Adult Liver Transplant Recipients: A Prospective Before-After Study","Inclusion Criteria:\n\n* Adult patients (age ≥ 18 years)\n* Undergoing or underwent (for the retrospective \"before\" group) primary orthotopic liver transplantation. Retrospective data collection for retrospective group will take place between January 1, 2020 - May 31, 2025.\n* Written informed consent obtained for patients in the prospective (\"after\") group\n\nExclusion Criteria:\n\n* History of pulmonary arterial hypertension (mean pulmonary artery pressure ≥ 25 mmHg)\n* Re-transplantation\n* Acute fulminant hepatitis\n* Combined organ transplantation (e.g., liver-kidney)\n* Lack of complete data for propensity matching - Inability to communicate in the English language",{"count":150,"type":21},260,[119],"Liver transplantation remains the only cure for patients with end-stage liver disease. Despite continuous advances in medical care, ischemia-reperfusion injury (IRI) (tissue damage that occurs when blood supply is restored to an area that has been deprived of oxygen) remains a major contributor to complications with the newly transplanted liver. IRI can lead to a condition known as post-reperfusion syndrome that involves profound narrowing of blood vessels, significantly low blood pressure, and an increased requirement of medication to control blood pressure. In some cases, post-reperfusion syndrome can progress to a condition known as post-reperfusion vasoplegia which is a condition where severely low blood pressure persists even after blood flow is restored to the liver. This is often accompanied by complications such as improperly functioning kidneys, blood clotting disorders, and complications with the transplanted liver that can significantly affect patient outcomes. Recent studies have shown than inhaled nitric oxide (a gas that can relax blood vessels) can reduce the severity of IRI in the liver. This study is being conducted to determine whether the administration of inhaled nitric oxide during surgery reduces the severity of post-reperfusion syndrome and the incidence of post-reperfusion vasoplegia in adult patients undergoing liver transplantation. This is a before-and-after study design that will involve both the retrospective collection of data between the time period of January 1, 2020 - May 31, 2025 and prospective interventions involving adult liver transplant recipients.",[154,155,29],"Liver Diseases","Reperfusion Injury",[157,158],"Inhaled Nitric Oxide","Anesthesia","2025-08-14",{"date":161,"type":34},"2025-08-15",{"date":163,"type":21},"2025-09-01",{"date":165,"type":21},"2027-01-01",{"name":167,"class":41},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":178,"briefSummary":180,"conditions":181,"keywords":182,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":195},"100563356","phase-3-reducing-cardiac-surgery-associated-acute-kidney-injury-occurence-by-administering-angiotensin-ii-100563356","NCT06615102","Reducing Cardiac-surgery Associated Acute Kidney Injury Occurence by Administering Angiotensin II","A Prospective Angiotensin II Versus Noradrenaline Trial for Hypotension Management to Reduce Cardiac-surgery Associated Acute Kidney Injury (PAN-AKI)","PAN-AKI","Inclusion Criteria:\n\n1. Cardiac surgery using cardiopulmonary bypass including coronary artery bypass grafting (CABG) surgery, valve surgery, or combined CABG\u002Fvalve surgery\n2. Elevated risk of AKI as predicted by a score ≥ 1.5 on the following scale:\n\n   1. hemoglobin \\\u003C 130g\u002Fl = 2\n   2. creatinine \\> 1.1 mg\u002Fdl = 2\n   3. age \\> 70 years =1.5\n   4. New York Heart Association Classification (NYHA) 4 =1.5\n   5. Body Mass Index (BMI) \\> 30 =1.5\n3. Adult ≥ 18 years\n4. Written informed consent\n\nExclusion Criteria:\n\n1. Major aortic surgery (aortic arch replacement), transplant surgery, pulmonary thrombendarterectomy, ventricular assist device placement\n2. Already receiving inotropic\u002Fvasopressor support before surgery\n3. Dialysis dependent\n4. Pre-existing AKI within the last 30 days\n5. Pre-existing chronic kidney injury with an eGFR\\\u003C20 ml\u002Fmin\u002F1.73m2\n6. Pre-existing significant hypertension (persistent SBP \\> 180mmHg)\n7. Significant pulmonary hypertension (ePSAP \\> 70mmHg, mPAP \\> 40mmHg) with right ventricular systolic dysfunction (graded more severe than mild)\n8. Hypersensitivity to the active substance or to any of the excipients\n9. Pregnancy (a negative pregnancy test for women of childbearing age) or breastfeeding women\n10. Persons with any kind of dependency on the investigator or employed by the sponsor\u002Finvestigator\n11. Participation in another interventional trial within the last three months that investigates kidney function",{"count":177,"type":21},1022,[179],"PHASE3","The study intervention focuses on exploring the use of angiotensin II as a primary vasopressor compared to norepinephrine in cardiac surgery patients to investigate whether angiotensin II can reduce the occurrence of moderate\u002Fsevere acute kidney injury (AKI). Despite its potential, as suggested by trials involving surgical patients, there is currently no human data confirming its effectiveness in preventing moderate\u002Fsevere AKI in this context. The intervention aims to address this gap by evaluating angiotensin II's impact compared to norepinephrine.",[89,29],[183,184,185],"cardiac surgery","acute kidney injury","Angiotensin II","2025-07-15",{"date":188,"type":34},"2025-07-18",{"date":190,"type":34},"2025-03-31",{"date":192,"type":21},"2027-04",{"name":194,"class":41},"Universität Münster",4,{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":206,"conditions":207,"keywords":208,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":141},"100503328","differential-regulation-of-raas-axis-in-patients-undergoing-cardiac-surgery-100503328","NCT05833828","Differential Regulation of RAAS-axis in Patients Undergoing Cardiac Surgery","Differences in Plasma Concentration of RAAS-axis Hormones in Patients Undergoing Cardiac Surgery With or Without Cardiopulmonary Bypass","RAAS-HLM","Inclusion Criteria:\n\n1. adult patients undergoing on- or off-pump coronary artery bypass graft surgery\n2. written informed consent\n\nExclusion Criteria:\n\n1. emergency surgery in the context of acute coronary syndrome\n2. ACE-inhibitor or Angiotensin 1 (AT1)-receptor-blocker intake that was not paused on the day of surgery\n3. Chronic kidney disease with estimated glomerular filtration rate (eGFR)\\\u003C30ml\u002Fmin\u002F1.73m²\n4. Severe structural lung disease (asbestosis, silicosis, severe sarcoidosis, tuberculosis, severe emphysema, chronic obstructive pulmonary disease (COPD) Gold 3-4, lung fibrosis)\n5. Chronic pulmonary hypertension\n6. Pregnancy or breastfeeding\n7. Persons with any kind of dependency on the investigator or employed by the institution responsible or investigator\n8. Persons held in an institution by legal or official order",{"count":205,"type":21},40,"This study investigates the question of whether there are differences in the plasma concentration of hormones of the RAAS-axis between patients undergoing on-pump cardiac surgery and those receiving off-pump surgery",[29,27],[209,210,211,183],"vasoplegia","vasoplegic shock","cardiopulmonary bypass","2024-12-06",{"date":214,"type":34},"2024-12-12",{"date":216,"type":34},"2023-08-24",{"date":218,"type":21},"2025-08",{"name":194,"class":41},{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":70},"100563214","characterisation-of-endothelial-cells-in-different-inflammatory-pathologies-100563214","NCT06613256","Characterisation of Endothelial Cells in Different Inflammatory Pathologies","JEDI-2","Inclusion Criteria:\n\nHealthy volunteer\n\n* Adult ≥ 18 years\n* Able and willing to give consent\n\nSurgical patients\n\n* Adult ≥ 18 years\n* Patients admitted to RSFT for planned major surgery\n\nCritically ill patients\n\n* Adult ≥ 18 years\n* Emergency admission to ICU at RSFT\n* Meets the sepsis 3.0 definition\n\nExclusion Criteria:\n\nHealthy volunteer\n\n* Not currently a patient within the hospital\n* Absence of inflammatory diseases and disorders including but not limited to arthritis, peripheral artery disease, vasculitis, diabetes, cardiovascular disease and CKD.\n* Not on immunomodulatory medications, such as corticosteroids\n* History of recent major trauma within the last 2 months (e.g., surgery or injury requiring hospitalisation)\n\nSurgical patients\n\n* Patients with restricted liberty, prisoners or under legal protection\n* Anticipated prohibitively difficult venous cannulation\n* Presenting with inflammatory diseases and disorders including but not limited to arthritis, peripheral artery disease, vasculitis, sepsis, diabetes with end organ damage, cardiovascular disease and CKD\n* Currently prescribed immunomodulatory medication or immunocompromised\n* Received chemotherapy within 2 weeks of predicted sampling\n* Receiving vasopressor support prior to surgery\n* History of recent major trauma within the last 2 months (e.g., surgery or injury requiring hospitalisation)\n\nCritically ill patients\n\n* Patients with restricted liberty, prisoners or under legal protection• Anticipated prohibitively difficult venous cannulation\n* Presenting with inflammatory diseases and disorders including but not limited to arthritis, peripheral artery disease, vasculitis, diabetes with end organ damage, cardiovascular disease and CKD.\n* Currently prescribed immunomodulatory medication or immunocompromised\n* Received chemotherapy within 2 weeks of predicted sampling.\n* History of recent major trauma within the last 2 months (e.g., surgery or injury requiring hospitalisation)",{"count":228,"type":21},105,"The goal of this observational study is to characterise changes in gene expression in endothelial cells in patients with either sepsis or post major abdominal surgery.\n\nThe main question we plan to answer is: 'What molecular pathways are differentially expressed during inflammatory pathologies?'",[231,29],"Sepsis","2024-09-23",{"date":234,"type":34},"2024-09-25",{"date":236,"type":34},"2024-07-16",{"date":238,"type":21},"2026-11-12",{"name":240,"class":41},"Royal Surrey County Hospital NHS Foundation Trust",{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":22,"phases":250,"briefSummary":251,"conditions":252,"keywords":255,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":70},"100510172","norepinephrine-weaning-guided-by-the-hypotension-prediction-index-in-vasoplegic-shock-after-cardiac-surgery-100510172","NCT05922982","Norepinephrine Weaning Guided by the Hypotension Prediction Index in Vasoplegic Shock After Cardiac Surgery","NORAHPI","Inclusion Criteria:\n\n* Age \\> 18 years\n* The patient was hospitalized in the cardiothoracic-vascular and respiratory intensive care unit of Amiens-Picardy University Hospital.\n* Patient scheduled for on-pomp cardiac surgery \\[coronary artery bypass grafting, valve replacement, ascending aorta replacement, or combined surgery (valve and bypass grafting)\\].\n* Introduction of norepinephrine post-surgery for the treatment of vasoplegic syndrome.\n* On-pomp cardiac surgery in less than 48 hours.\n* Hemodynamically stable patient with MAP \\> 65 mmHg for more than 4 hours on noradrenaline\n* Monitoring of MAP with a radial or femoral arterial catheter\n* Social security beneficiary\n* Signature of the consent to participate in the study by the patient, preoperatively\n\nExclusion Criteria:\n\n* Permanent arrhythmia (atrial fibrillation, flutter, or frequent atrial extrasystoles).\n* Treatment with dobutamine, epinephrine, or vasopressin analog\n* Patients with preoperative chronic end-stage renal failure require postoperative extra-renal purification.\n* Pregnant woman\n* The patient is dependent on an internal or external pacemaker.\n* Hypothermia \\\u003C 36°.\n* Patient under mechanical circulatory assistance after cardiac surgery.\n* Hemorrhagic shock\n* Patient under guardianship or curators",{"count":249,"type":21},142,[119],"In postoperative cardiac surgery under extracorporeal circulation, the patient may develop a vasoplegic syndrome, characterized by arterial hypotension (mean arterial pressure (MAP) \\\u003C 65 mmHg); a decrease in vascular resistance and a cardiac output that may be normal or increased, and increased postoperative mortality\u002F International recommendations recommend the prescription of noradrenaline as a first-line treatment to reduce morbidity and mortality. However, excess norepinephrine or duration of exposure is also deleterious. The Acumen IQ device (Edwards Lifesciences) allows the calculation of a predictive index of arterial hypotension episodes (predictive hypotension index, HPI). HPI could improve norepinephrine weaning by preventing episodes of arterial hypotension or detecting preload dependence, thus avoiding the transient increase in norepinephrine during hypotension.\n\nThis is a single-center, prospective, open-label, randomized, controlled, 2-group, parallel, intention-to-treat study. The aim was to evaluate the superiority of a new decision algorithm, based on the HPI delivered by the Acumen IQ device, to reduce the duration of norepinephrine administration in post-cardiac surgery vasoplegic shock.\n\nThe duration of the interventional protocol is 72 hours. To evaluate the clinical impact of the protocol, the time of the study will be 30 days. Several follow-up visits will be performed (end-of-protocol day, discharge day, and at D30 of inclusion) to collect clinical, biological, and HPI monitoring data.",[29,253,127,254],"Shock","Surgery",[209,58,256,257,258,259,260],"hypotension prediction index","Acumen","CABG","norepinephrine","surgery","2024-07-02",{"date":263,"type":34},"2024-07-03",{"date":265,"type":34},"2023-09-01",{"date":267,"type":21},"2025-07",{"name":269,"class":41},"Centre Hospitalier Universitaire, Amiens"]